この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2021/6/111 分で読めます
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) published a notice in the Federal Register of February 12, 2018. After review of a timely request for reconsideration by the applicant of the determination of the regulatory review period of the animal drug, BRAVECTO, in that notice, FDA has determined that a revision of the SUPPLEMENTARY INFORMATION section is warranted. This document presents the revised regulatory review period.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →